Reptin drives tumour progression and resistance to chemotherapy in non-small cell lung cancer
European Respiratory Journal Jun 09, 2018
Mikesch JH, et al. - As researchers found the AAA+ ATPase Reptin to be highly expressed in the vast majority of 278 non-small cell lung cancer (NSCLC) tumour samples, they evaluated the role of Reptin in NSCLC. They found that high RNA expression levels of Reptin were associated with adverse outcome, as revealed in survival analyses of NSCLC patients. They identified that Reptin had a role as a novel independent prognostic factor. Furthermore, its role as a key regulator mediating proliferation and clonal growth of human NSCLC cells ex vivo and in vivo was also shown. In addition, a Reptin/histone deacetylase 1 (HDAC1) protein complex was also discovered whose pharmacological disruption was shown to sensitize NSCLC cells to cisplatin.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries